Skip to main content
. Author manuscript; available in PMC: 2021 Mar 29.
Published in final edited form as: Leukemia. 2016 Nov 24;31(6):1286–1295. doi: 10.1038/leu.2016.345

Figure 4. AML patients with LM-CH have a high risk of relapse.

Figure 4

(A) Mutation pattern of paired diagnosis and relapse samples of 20 DNMT3A mutated patients.

(B) Cumulative incidence of relapse (CIR) in patients with LM-CH, patients without LM-CH who are DNMT3A mutated in CR (M-CH), and patients without LM-CH who are DNMT3A wildtype in CR.